País: Canadá
Língua: inglês
Origem: Health Canada
GRANISETRON (GRANISETRON HYDROCHLORIDE)
APOTEX INC
A04AA02
GRANISETRON
1MG
TABLET
GRANISETRON (GRANISETRON HYDROCHLORIDE) 1MG
ORAL
10/20/1000
Prescription
5-HT3 RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0123183001; AHFS:
APPROVED
2016-07-08
Page 1 of 29 PRODUCT MONOGRAPH Pr APO-GRANISETRON GRANISETRON HYDROCHLORIDE TABLETS, USP 1 MG GRANISETRON (AS GRANISETRON HYDROCHLORIDE) ANTIEMETIC/5-HT 3 RECEPTOR ANTAGONIST APOTEX INC. DATE OF PREPARATION: 150 SIGNET DRIVE JUNE 30, 2016 TORONTO, ONTARIO M9L 1T9 CONTROL NO.: 194711 Page 2 of 29 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................ 4 WARNINGS AND PRECAUTIONS ....................................................................................... 4 ADVERSE REACTIONS ......................................................................................................... 6 DRUG INTERACTIONS ......................................................................................................... 9 DOSAGE AND ADMINISTRATION ................................................................................... 10 OVERDOSAGE ...................................................................................................................... 11 ACTION AND CLINICAL PHARMACOLOGY ................................................................. 11 STORAGE AND STABILITY ............................................................................................... 13 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................. 14 PART II: SCIENTIFIC INFORMATION ............................................................................. 15 PHARMACEUTICAL INFORMATION ............................................................................... 15 CLINICAL TRIALS ............................................................................................................... 17 DET Leia o documento completo